AAAAAA

   
Results: 1-8 |
Results: 8
Effect of parathyroid hormone (1-34) on fractures and bone mineral densityin postmenopausal women with osteoporosis.
Authors: Neer, RM Arnaud, CD Zanchetta, JR Prince, R Gaich, GA Reginster, JY Hodsman, AB Eriksen, EF Ish-Shalom, S Genant, HK Wang, OH Mitlak, BH
Citation: Rm. Neer et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral densityin postmenopausal women with osteoporosis., N ENG J MED, 344(19), 2001, pp. 1434-1441
Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle
Authors: Chiu, KM Arnaud, CD Ju, J Mayes, D Bacchetti, P Weitz, S Keller, ET
Citation: Km. Chiu et al., Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle, BONE, 26(1), 2000, pp. 79-85
Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis
Authors: Lane, NE Sanchez, S Genant, HK Jenkins, DK Arnaud, CD
Citation: Ne. Lane et al., Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis, OSTEOPOR IN, 11(5), 2000, pp. 434-442
Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
Authors: Lane, NE Sanchez, S Modin, GW Genant, HK Pierini, E Arnaud, CD
Citation: Ne. Lane et al., Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial, J BONE MIN, 15(5), 2000, pp. 944-951
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women - Three-year data from 2double-blind, randomized, placebo-controlled trials
Authors: Johnston, CC Bjarnason, NH Cohen, FJ Shah, A Lindsay, R Mitlak, BH Huster, W Draper, MW Harper, KD Heath, H Gennari, C Christiansen, C Arnaud, CD Delmas, PD
Citation: Cc. Johnston et al., Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women - Three-year data from 2double-blind, randomized, placebo-controlled trials, ARCH IN MED, 160(22), 2000, pp. 3444-3450
Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions
Authors: Uda, K Kobayashi, Y Hisada, T Orlowski, RC Bastian, JW Arnaud, CD Wakabayashi, K
Citation: K. Uda et al., Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions, BIOL PHAR B, 22(3), 1999, pp. 244-252
Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures
Authors: Bauer, DC Sklarin, PM Stone, KL Black, DM Nevitt, MC Ensrud, KE Arnaud, CD Genant, HK Garnero, P Delmas, PD Lawaetz, H Cummings, SR
Citation: Dc. Bauer et al., Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures, J BONE MIN, 14(8), 1999, pp. 1404-1410
Changes in bone resorption during the menstrual cycle
Authors: Chiu, KM Ju, J Mayes, D Bacchetti, P Weitz, S Arnaud, CD
Citation: Km. Chiu et al., Changes in bone resorption during the menstrual cycle, J BONE MIN, 14(4), 1999, pp. 609-615
Risultati: 1-8 |